Publication | Open Access

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Gastrointestinal OncologyMedicinePharmacologyColorectal CancerMetastatic Colorectal CancerPhase Ii StudyPharmacotherapyAnti-cancer AgentCancer TreatmentSecond-line TherapyOncologyRadiation OncologyMolecular Oncology